Welcome to The TAPESTRY AUTISM Study

If your child has a diagnosis of autism and struggles with irritability, they may qualify to participate in our clinical trial of a potential new treatment.

Who is this study for?

- Male or female teens may qualify for this study if they meet the following criteria:
  - Are age 13 to 17
  - Have been diagnosed with ASD
  - Experience irritability

A New Approach to Treating Autism-Related Irritability

The clinical trials evaluating an experimental drug, AB-204, offers a novel approach for the treatment of irritability associated with Autism Spectrum Disorder (ASD). This study builds upon research that has shown there is a significant difference in the bacteria located in the gut or digestive tract of children with autism compared to those children who are not on the autism spectrum. Scientific evidence has demonstrated there may be a link between gut bacteria and the brain which could contribute to certain characteristics, such as irritability, in children with ASD.

AB-204, which is a powder, is designed to selectively absorb substances produced by bacteria in the gut and reduce their ability to enter the bloodstream and contribute to certain characteristics like irritability. The TAPESTRY Study is a placebo-controlled clinical trial that aims to show that treatment with AB-204 can improve irritability in children with ASD. Eligible participants will be randomly assigned to receive AB-204 or placebo.

Who is this study for?

- Male or female teens may qualify for this study if they meet the following criteria:
  - Are age 13 to 17
  - Have been diagnosed with ASD
  - Experience irritability

Learn more about the study

What will participants receive?

- If your child qualifies for this study, they will receive, at no cost:
  - The investigational drug or placebo
  - All study-related assessments conducted by trained staff at our clinical sites
  - Health insurance is not required to take part in this study.

Where are the study locations?

The TAPESTRY study is being conducted at 35 major clinical centers in the United States, Australia, and New Zealand.
Is My Child Eligible?

Easing the study enrollment process

The safety of your child is our top priority. That's why all parents and caregivers understandably have questions and concerns about the clinical trial process. That's why we've created this site to provide helpful information that makes the enrollment process a little easier for families. Before participating in the trial, we must determine your child's eligibility. Here's a quick guide to the eligibility criteria:

**IF YOUR CHILD IS:**

- Male or Female
- 13–17 years old
- Highly Irritable

**IS ABLE TO ATTEND CLINIC APPOINTMENTS IN PERSON**

**HAS A PARENT OR CAREGIVER WHO CAN READ, WRITE AND SPEAK ENGLISH TO COMPLETE STUDY ASSESSMENTS**

If you think your child is eligible for the study and may benefit from the experimental treatment, take the next step:

See if your child qualifies

"The severity of daily challenges faced by people with autism, combined with the lack of safe and effective treatment options, has resulted in a significant unmet need for innovative medical interventions."

— Raul D. Wieden, M.D., co-founder and medical director of the Southwest Autism Research and Resource Center, who is a principal investigator for the AB-2004 study

"The AB-2004 clinical trial program offers potential hope for children with ASD who too often struggle with anxiety and irritability such that it permeates all aspects of daily life."

STUDY LOCATIONS
Easing the study enrollment process

To enable easier access to the clinical trial for children and their families, 25 locations for The TAPESTRY Study are planned across the United States, Australia and New Zealand. Eligible participants will be randomly assigned to receive AB-2004 or placebo and all study-related assessments of no cost. Expenses for travel to and from the doctor and medical visits will be paid for by Axial Therapeutics. Additional information around travel reimbursement will be provided by the trial coordinator.

More information is also available at: clinicaltrials.gov identifier NCT04995213.

If you think your child is eligible for the study and may benefit from the experimental treatment, take the next step:

See if your child qualifies >

“The lack of safe and effective treatment options for co-occurring conditions associated with ASD, such as irritability and anxiety, exacerbate the daily challenges faced by children and their families.”

—Robert L. Hendren, D.O., professor of psychiatry, Weil Institute for Neurosciences at the University of California, San Francisco, School of Medicine, and a principal investigator for the AB-2004 Phase 3 trial

“I am encouraged by previous studies of AB-2004 and I look forward to assessing its potential as a safe alternative to atypical antipsychotics currently used to treat irritability associated with autism.”